These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38607409)

  • 21. Short-Term Outcomes of 3 Monthly intravitreal Faricimab On Different Subtypes of Neovascular Age-Related Macular Degeneration.
    Tanaka A; Hata M; Tsuchikawa M; Ueda-Arakawa NU; Tamura H; Miyata M; Takahashi A; Kido A; Muraoka Y; Miyake M; Ooto S; Tsujikawa A
    Clin Ophthalmol; 2024; 18():507-516. PubMed ID: 38405104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term outcomes of intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration.
    Matsumoto H; Hoshino J; Nakamura K; Nagashima T; Akiyama H
    Graefes Arch Clin Exp Ophthalmol; 2023 Oct; 261(10):2945-2952. PubMed ID: 37195339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study.
    Grimaldi G; Cancian G; Rizzato A; Casanova A; Perruchoud-Ader K; Clerici M; Consigli A; Menghini M
    Graefes Arch Clin Exp Ophthalmol; 2024 Apr; 262(4):1151-1159. PubMed ID: 38047930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration.
    Leung EH; Oh DJ; Alderson SE; Bracy J; McLeod M; Perez LI; Bottini A; Chin Yee D; Mukkamala K
    Clin Ophthalmol; 2023; 17():1287-1293. PubMed ID: 37181079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
    Braimah IZ; Agarwal K; Mansour A; Chhablani J;
    Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characteristics and visual outcomes of non-resolving subretinal fluid in neovascular AMD despite continuous monthly anti-VEGF injections: a long-term follow-up.
    Hosseini H; Rabina G; Pettenkofer M; Au A; Chehaibou I; Heilweil G; Weiner AJ; Ip M; Loewenstein A; Schwartz SD
    Graefes Arch Clin Exp Ophthalmol; 2021 May; 259(5):1153-1160. PubMed ID: 33245430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration.
    Inan S; Polat O; Karadas M; Inan UU
    Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of intravitreal ranibizumab, aflibercept and bevacizumab on retinal ganglion cell and nerve fibre layer thickness in Neovascular age-related macular degeneration.
    Abu Dail Y; Seitz B; Sideroudi H; Abdin AD
    Acta Ophthalmol; 2023 May; 101(3):330-341. PubMed ID: 36345883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association Between Visual Acuity and Residual Retinal Fluid Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-analysis.
    Patil NS; Mihalache A; Dhoot AS; Popovic MM; Muni RH; Kertes PJ
    JAMA Ophthalmol; 2022 Jun; 140(6):611-622. PubMed ID: 35551359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration.
    Rush RB
    Clin Ophthalmol; 2023; 17():2201-2208. PubMed ID: 37547172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment.
    Takahashi H; Inoda S; Takahashi H; Takahashi R; Hashimoto Y; Yoshida H; Kawashima H; Yanagi Y
    Sci Rep; 2024 Apr; 14(1):9087. PubMed ID: 38643252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-Term Morphofunctional Changes in Previously Treated Neovascular AMD Eyes Switched to Brolucizumab.
    Viggiano P; Grassi MO; Boscia G; Pignataro M; Petruzzella G; Borrelli E; Molfetta T; Alessio G; Boscia F
    J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Volumetric fluid analysis of fixed monthly anti-VEGF treatment in patients with neovascular age-related macular degeneration.
    Kim BH; Chang IB; Yu HG; Hong IH
    Int J Ophthalmol; 2023; 16(6):909-914. PubMed ID: 37332546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retention of good visual acuity in eyes with neovascular age-related macular degeneration and chronic refractory subfoveal subretinal fluid.
    Bhavsar KV; Freund KB
    Saudi J Ophthalmol; 2014 Apr; 28(2):129-33. PubMed ID: 24843306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Loading Dose between Aflibercept and Faricimab for Neovascular Age-Related Macular Degeneration.
    Hara C; Suzue M; Fujimoto S; Fukushima Y; Sayanagi K; Nishida K; Maruyama K; Sato S; Nishida K
    J Clin Med; 2024 Jan; 13(2):. PubMed ID: 38256517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.
    Agostini H; Abreu F; Baumal CR; Chang DS; G Csaky K; Demetriades AM; Kodjikian L; Lim JI; Margaron P; Monés JM; Peto T; Ricci F; Rüth M; Singh RP; Stoilov I; Swaminathan B; Willis JR; Westenskow PD
    Graefes Arch Clin Exp Ophthalmol; 2024 Jun; ():. PubMed ID: 38847896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results.
    Khanani AM; Aziz AA; Khan H; Gupta A; Mojumder O; Saulebayeva A; Abbey AM; Almeida DRP; Avery RL; Banda HK; Barakat MR; Bhandari R; Chang EY; Haug SJ; London NJS; Mein L; Sheth VS; Wolfe JD; Singer MA; Danzig CJ
    Eye (Lond); 2023 Dec; 37(17):3574-3581. PubMed ID: 37173428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study).
    Fung AT; Kumar N; Vance SK; Slakter JS; Klancnik JM; Spaide RS; Freund KB
    Eye (Lond); 2012 Sep; 26(9):1181-7. PubMed ID: 22878451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration.
    Hikichi T
    Jpn J Ophthalmol; 2023 Nov; 67(6):652-656. PubMed ID: 37861941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.